These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
70 related articles for article (PubMed ID: 22253134)
1. Evaluating the interaction between the therapy and the treatment in clinical trials by the propensity score weighting method. Fujii Y; Henmi M; Fujita T Stat Med; 2012 Feb; 31(3):235-52. PubMed ID: 22253134 [TBL] [Abstract][Full Text] [Related]
2. Rationale, design and patient baseline characteristics of OlmeSartan and calcium antagonists randomized (OSCAR) study: a study comparing the incidence of cardiovascular events between high-dose angiotensin II receptor blocker (ARB) monotherapy and combination therapy of ARB with calcium channel blocker in Japanese elderly high-risk hypertensive patients (ClinicalTrials. gov no. NCT00134160). Ogawa H; Kim-Mitsuyama S; Jinnouchi T; Matsui K; Arakawa K Hypertens Res; 2009 Jul; 32(7):575-80. PubMed ID: 19444280 [TBL] [Abstract][Full Text] [Related]
3. Generalized propensity score for estimating the average treatment effect of multiple treatments. Feng P; Zhou XH; Zou QM; Fan MY; Li XS Stat Med; 2012 Mar; 31(7):681-97. PubMed ID: 21351291 [TBL] [Abstract][Full Text] [Related]
4. Model misspecification and robustness in causal inference: comparing matching with doubly robust estimation. Waernbaum I Stat Med; 2012 Jul; 31(15):1572-81. PubMed ID: 22359267 [TBL] [Abstract][Full Text] [Related]
5. Antihypertensive efficacy and tolerability of two fixed-dose combinations of valsartan and hydrochlorothiazide compared with valsartan monotherapy in patients with stage 2 or 3 systolic hypertension: an 8-week, randomized, double-blind, parallel-group trial. Lacourcière Y; Poirier L; Hebert D; Assouline L; Stolt P; Rehel B; Khder Y Clin Ther; 2005 Jul; 27(7):1013-21. PubMed ID: 16154480 [TBL] [Abstract][Full Text] [Related]
6. Exploratory analyses of efficacy data from major depressive disorder trials submitted to the US Food and Drug Administration in support of new drug applications. Khin NA; Chen YF; Yang Y; Yang P; Laughren TP J Clin Psychiatry; 2011 Apr; 72(4):464-72. PubMed ID: 21527123 [TBL] [Abstract][Full Text] [Related]
7. [Comparison of benazepril monotherapy to amlodipine plus benazepril in the treatment of patients with mild and moderate hypertension: a multicentre, randomized, double-blind, parallel-controlled study]. Fan CM; Yan LR; Tao YK; Wang L; Li YQ; Gao MM; Wang YN; Li CX; Wang XW; Lu XL; Pang HM; Li YS Zhonghua Xin Xue Guan Bing Za Zhi; 2011 Jan; 39(1):57-60. PubMed ID: 21418799 [TBL] [Abstract][Full Text] [Related]
8. Comparison of Nebivolol monotherapy versus Nebivolol in combination with other antihypertensive therapies for the treatment of hypertension. Papademetriou V Am J Cardiol; 2009 Jan; 103(2):273-8. PubMed ID: 19121451 [TBL] [Abstract][Full Text] [Related]
9. Efficacy and tolerability of nebivolol monotherapy by baseline systolic blood pressure: a retrospective analysis of pooled data from two multicenter, 12-week, randomized, double-blind, placebo-controlled, parallel-group, dose-ranging studies in patients with mild to moderate essential hypertension. Germino FW Clin Ther; 2009 Sep; 31(9):1946-56. PubMed ID: 19843484 [TBL] [Abstract][Full Text] [Related]
10. Initial angiotensin-converting enzyme inhibitor/calcium channel blocker combination therapy achieves superior blood pressure control compared with calcium channel blocker monotherapy in patients with stage 2 hypertension. Jamerson KA; Nwose O; Jean-Louis L; Schofield L; Purkayastha D; Baron M Am J Hypertens; 2004 Jun; 17(6):495-501. PubMed ID: 15177521 [TBL] [Abstract][Full Text] [Related]
11. Marginal mean weighting through stratification: a generalized method for evaluating multivalued and multiple treatments with nonexperimental data. Hong G Psychol Methods; 2012 Mar; 17(1):44-60. PubMed ID: 21843003 [TBL] [Abstract][Full Text] [Related]
12. Amlodipine and angiotensin-converting enzyme inhibitor combination versus amlodipine monotherapy in hypertension: a meta-analysis of randomized controlled trials. Lv Y; Zou Z; Chen GM; Jia HX; Zhong J; Fang WW Blood Press Monit; 2010 Aug; 15(4):195-204. PubMed ID: 20512032 [TBL] [Abstract][Full Text] [Related]
13. A multicenter, randomized, double-blind, parallel-group trial of the antihypertensive efficacy and tolerability of a combination of once-daily losartan 100 mg/hydrochlorothiazide 12.5 mg compared with losartan 100-mg monotherapy in the treatment of mild to severe essential hypertension. Gleim GW; Rubino J; Zhang H; Shahinfar S; Soffer BA; Lyle PA; Littlejohn TW; Feig PU Clin Ther; 2006 Oct; 28(10):1639-48. PubMed ID: 17157119 [TBL] [Abstract][Full Text] [Related]
14. Efficacy and tolerability of combination therapy with valsartan plus hydrochlorothiazide compared with amlodipine monotherapy in hypertensive patients with other cardiovascular risk factors: the VAST study. Ruilope LM; Malacco E; Khder Y; Kandra A; Bönner G; Heintz D Clin Ther; 2005 May; 27(5):578-87. PubMed ID: 15978306 [TBL] [Abstract][Full Text] [Related]
15. An 18-week, prospective, randomized, double-blind, multicenter study of amlodipine/ramipril combination versus amlodipine monotherapy in the treatment of hypertension: the assessment of combination therapy of amlodipine/ramipril (ATAR) study. Miranda RD; Mion D; Rocha JC; Kohlmann O; Gomes MA; Saraiva JF; Amodeo C; Filho BL Clin Ther; 2008 Sep; 30(9):1618-28. PubMed ID: 18840367 [TBL] [Abstract][Full Text] [Related]
16. Estimators and confidence intervals for the marginal odds ratio using logistic regression and propensity score stratification. Stampf S; Graf E; Schmoor C; Schumacher M Stat Med; 2010 Mar; 29(7-8):760-9. PubMed ID: 20213703 [TBL] [Abstract][Full Text] [Related]
17. Estimation of treatment effect adjusting for treatment changes using the intensity score method: application to a large primary prevention study for coronary events (MEGA study). Tanaka Y; Matsuyama Y; Ohashi Y; Stat Med; 2008 May; 27(10):1718-33. PubMed ID: 17922525 [TBL] [Abstract][Full Text] [Related]
18. [Calcium antagonists in cardiovascular disease. Clinical evidence from morbidity and mortality trials]. Oparil S; Bakir SE Drugs; 2000; 59 Spec No 2():25-37. PubMed ID: 11002856 [TBL] [Abstract][Full Text] [Related]
19. Interpreting quality-of-life clinical trial data for use in the clinical practice of antihypertensive therapy. Testa MA J Hypertens Suppl; 1987 Feb; 5(1):S9-13. PubMed ID: 3553497 [TBL] [Abstract][Full Text] [Related]
20. Sequentially adjusted randomization to force balance in controlled trials with unknown prevalence of covariates: application to alcoholism research. Müller MJ; Scheurich A; Wetzel H; Szegedi A; Hautzinger M Alcohol Alcohol; 2005; 40(2):124-31. PubMed ID: 15642723 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]